India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new opportunities to expand access to their medicines through PAPs.

India is poised to capture a bigger share of the global pharmaceutical manufacturing market beyond generics, according to a ...

The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now ...

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue ...

Out of the 41 analysts that have coverage on Sun Pharma, 30 of them have a 'Buy' rating on the stock. Seven of them have a ...

Pharma stocks had a mixed response after Finance Minister Nirmala Sitharaman announced customs duty exemptions for 36 essential drugs and reduced rates for six others.

The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24.

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

There is a need to focus on innovation, new drug development and biopharmaceuticals as spending on research and development ...

In a significant shift in the global pharmaceutical landscape, a substantial portion of French medicines is now being ...

New Delhi [India], January 27 (ANI): India is poised to capture a bigger share of the global pharmaceutical manufacturing market beyond generics, according to a report by Boston Consulting Group ...